Talampanel

Talampanel (LY300164) is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor antagonis with anti-seizure activity[1]. Talampanel (IVAX) has neuroprotective effects in rodent stroke models[2]. Talampanel attenuates caspase-3 dependent apoptosis in mouse brain[2].

Product Specifications

CAS Number

[161832-65-1]

Product Name Alternative

GYKI-53773; LY-300164

UNSPSC

12352005

Hazard Statement

H301, H401

Target

Apoptosis; iGluR

Type

Reference compound

Related Pathways

Apoptosis; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Talampanel.html

Concentration

10mM

Purity

99.77

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@H]1CC2=C(C=C(OCO3)C3=C2)C(C4=CC=C(N)C=C4)=NN1C(C)=O

Molecular Formula

C19H19N3O3

Molecular Weight

337.37

Precautions

H301, H401

References & Citations

[1]Paizs M, et al. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler. 2011 Sep;12 (5) :340-4.|[2]Denes L, et al. Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia. Brain Res Bull. 2006 Jul 31;70 (3) :260-2. Epub 2006 Mar 31.